KBL Merger Corp. IV (NASDAQ: KBLM or the “Company”), a special purpose acquisition company (SPAC) that previously announced an agreement to acquire 180 Life Sciences Corp. (“180 Life Sciences”), announced Friday that a special meeting (the “Meeting”) of the stockholders of KBL Merger Corp. IV (the “Company”) was held on November 5, 2020, where all proposals, including the proposal to approve the proposed business combination with 180 Life Sciences, were approved.
The Planet Group (“Planet”), a leading provider of outsourced human capital and consulting solutions and a portfolio company of MidOcean Partners, announced today that it has entered into an agreement to acquire NDA Partners, a global life sciences management consulting and contract development organization focused on providing innovative product development and regulatory services to the pharmaceutical, biotechnology and medical device industries. Headquartered outside of Washington, DC, NDA Partners was founded in 2003 by 10 former FDA officials and pharmaceutical industry executives who have pioneered some of the most innovative modern approaches to medical product development and regulatory review.
Milton Street Capital, a Houston-based lower middle market private equity firm, announced the simultaneous acquisition of the Life Sciences business of Worthington Industries and International Cryogenics, Inc. Following the closing, these two cryogenic biomedical equipment manufacturers will operate under IC Biomedical. The Life Sciences business of Worthington Industries (“Life Sciences”), located in Theodore, AL, is a market leading manufacturer of cryogenic stainless steel and aluminum storage freezers, dewars and shippers used to store biological specimens. International Cryogenics, Inc. (“ICI”), based in Indianapolis, IN, is a manufacturer of cryogenic aluminum, freezers, dewars, shippers and custom products for biomedical applications.
PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) and Horizon Discovery Group plc (LSE: HZD) (“Horizon”) are pleased to announce that they have reached an agreement on the terms of a recommended all cash offer whereby PerkinElmer will acquire Horizon for approximately $383 million (£296 million). The transaction has a total enterprise value of approximately $368 million (£284 million), is expected to close in the first quarter of 2021 subject to customary closing conditions. With this investment, PerkinElmer will expand its portfolio of leading, automated life sciences discovery and applied genomics solutions to include gene editing and gene modulation tools. Headquartered in Cambridge, UK, Horizon is a leading provider of CRISPR and RNAi reagents, cell models, cell engineering and base editing offerings which help scientists better understand gene function, genetic disease drivers and biotherapeutics delivery.
Sana Biotechnology, Inc. (Sana), focused on creating and delivering engineered cells as medicines, announced today the acquisition of Oscine Corp., a company developing potentially curative or disease modifying cell therapies for diseases of the brain and central nervous system (CNS). The combination will integrate Oscine’s glial progenitor cell program and underlying technologies together with Sana’s broader platform and programs. Terms of the acquisition were not disclosed.
Vedere Bio, Inc. (Vedere Bio), a stealth-stage company focused on advancing photoreceptor-protein-based optogenetic therapies that are delivered to the retina intravitreally to restore functional vision, announced today that it has been acquired by Novartis. Shareholders in Vedere Bio received $150 million upfront and will be eligible for up to $130 million in milestone payments, for a total of $280 million. Based on technology from the laboratories of Drs. Ehud Isacoff and John G. Flannery of UC Berkeley, and technology directed at enhanced ocular gene therapy delivery arising jointly between UC Berkeley and the School of Veterinary Medicine at the University of Pennsylvania, Vedere Bio was formed in the Atlas Venture incubator in June 2019.
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, announced Tuesday that it has entered into a definitive agreement to acquire privately-held ARTeSYN Biosolutions (“ARTeSYN”) for approximately $200 million, comprised of approximately $130 million in cash and approximately $70 million in Repligen common stock. The proposed acquisition of ARTeSYN, combined with the recent acquisitions of Engineered Molding Technologies (“EMT”) and Non-Metallic Solutions (“NMS”) further establishes Repligen as a premier player in single-use systems and associated integrated flow path assemblies.
miRagen Therapeutics, Inc. (“miRagen”) (NASDAQ: MGEN) today announced it has completed the acquisition of Viridian Therapeutics, Inc. (“Viridian”), a privately held biotechnology company focused on advancing new treatments for patients with diseases that are underserved by today’s therapies. Concurrent with the acquisition of Viridian, miRagen entered into a definitive agreement for the sale of Series A non-voting convertible preferred stock (the “Series A preferred stock”) in a private placement to a group of institutional accredited investors.
Calibre Scientific is pleased to announce the acquisition of Dianova GmbH, a life science manufacturer and distributor. Dianova will be integrated with BIOZOL Diagnostica GmbH, a subsidiary of Calibre Scientific, creating a distribution network to service the DACH region. Based in Hamburg, Germany, Dianova is a distributor of antibodies, immunoassays, and products for molecular biology, and a manufacturer of highly validated primary antibodies for histopathology. Laboratory professionals in Germany, Austria, and Switzerland rely on Dianova for its decades of expertise, comprehensive customer support, user-friendly solutions, and high-quality products.
Bayer AG today announced the acquisition of Asklepios BioPharmaceutical, Inc. (AskBio), a US-headquartered biopharmaceutical company specialized in the research, development and manufacturing of gene therapies across different therapeutic areas. AskBio’s development portfolio includes investigational pre-clinical and clinical stage candidates for the treatment of neuromuscular, central nervous system, cardiovascular and metabolic diseases.
What We Do
Who We Are
How We Work
Who We Help
Get In Touch
Connect With Us
Subscribe to Our Daily Note
We publish a Daily Note that aggregates M&A activity, notable developments, regulatory changes, and conferences we deem to be of interest to our partners. It is a quick afternoon read and an easy way to keep your finger on the pulse of the healthcare space. Please fill in your name and email address below if you wish to subscribe.